AU Patent

AU2004288715A1 — Methods of using and compositions comprising a JNK inhibitor for the treatment and management of asbestos-related diseases and disorders

Assigned to Celgene Corp · Expires 2005-05-26 · 21y expired

What this patent protects

Patent listed against Otezla.

Drugs covered by this patent

Patent Metadata

Patent number
AU2004288715A1
Jurisdiction
AU
Classification
—
Expires
2005-05-26
Drug substance claim
No
Drug product claim
No
Assignee
Celgene Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.